EPISODE · Jun 12, 2023 · 11 MIN
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
from OncLive® On Air · host OncLive® On Air
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
Embed this episode
NOW PLAYING
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
0:00
11:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncLive® On Air?
This episode is 11 minutes long.
When was this OncLive® On Air episode published?
This episode was published on June 12, 2023.
Can I download this OncLive® On Air episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!